Oral activity of the antimalarial endoperoxide 6-(1,2,6,7-tetraoxaspiro[7.11]nonadec-4-yl)hexan-1-ol (N-251) against Leishmania donovani complex

Show simple item record

dc.contributor.author Kwofie, K.D.
dc.contributor.author Sato, K.
dc.contributor.author Sanjoba, C.
dc.contributor.author Hino, A.
dc.contributor.author Shimogawara, R.
dc.contributor.author Amoa-Bosompem, M.
dc.contributor.author Ayi, I.
dc.contributor.author Boakye, D.A.
dc.contributor.author Anang, A.K.
dc.contributor.author Chang, K.S.
dc.contributor.author Ohashi, M.
dc.contributor.author Kim, H.S.
dc.contributor.author Ohta, N.
dc.contributor.author Matsumoto, Y.
dc.contributor.author Iwanaga, S.
dc.date.accessioned 2019-05-21T09:01:47Z
dc.date.available 2019-05-21T09:01:47Z
dc.date.issued 2019-03
dc.identifier.citation Kwofie KD, Sato K, Sanjoba C, Hino A, Shimogawara R, Amoa-Bosompem M, et al. (2019) Oral activity of the antimalarial endoperoxide 6-(1,2,6,7-tetraoxaspiro[7.11]nonadec-4-yl)hexan-1-ol (N-251) against Leishmania donovani complex. PLoS Negl Trop Dis 13(3): e0007235. https://doi.org/10.1371/journal.pntd.0007235 en_US
dc.identifier.other https://doi.org/10.1371/journal.pntd.0007235
dc.identifier.uri http://ugspace.ug.edu.gh/handle/123456789/30125
dc.description.abstract Visceral leishmaniasis (VL) is a major problem worldwide and causes significant morbidity and mortality. Existing drugs against VL have limitations, including their invasive means of administration long duration of treatment regimens. There are also concerns regarding increasing treatment relapses as well as the identification of resistant clinical strains with the use of miltefosine, the sole oral drug for VL. There is, therefore, an urgent need for new alternative oral drugs for VL. In the present study, we show the leishmanicidal effect of a novel, oral antimalarial endoperoxide N-251. In our In vitro studies, N-251 selectively and specifically killed Leishmania donovani D10 amastigotes with no accompanying toxicity toward the host cells. In addition, N-251 exhibited comparable activities against promastigotes of L. donovani D10, as well as other L. donovani complex parasites, suggesting a wide spectrum of activity. Furthermore, even after a progressive infection was established in mice, N-251 significantly eliminated amastigotes when administered orally. Finally, N-251 suppressed granuloma formation in mice liver through parasite death. These findings indicate the therapeutic effect of N-251 as an oral drug, hence suggest N-251 to be a promising lead compound for the development of a new oral chemotherapy against VL. en_US
dc.language.iso en en_US
dc.publisher PLoS neglected tropical diseases en_US
dc.title Oral activity of the antimalarial endoperoxide 6-(1,2,6,7-tetraoxaspiro[7.11]nonadec-4-yl)hexan-1-ol (N-251) against Leishmania donovani complex en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

  • Parasitology Department [244]
    The Department of Parasitology conducts research into parasitic diseases of public health importance with the overall goal of reducing their transmission and the heavy disease burden that they impose on affected populations. The Department maintains focus on parasitic diseases in general. These include major diseases such as malaria, and others listed under the Neglected Tropical Diseases (NTD) control initiative such as, lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiasis, trypanosomiasis and leishmaniasis.

Show simple item record

Search UGSpace


Browse

My Account